These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 23625979)
1. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples. Combe B; van Vollenhoven R Ann Rheum Dis; 2013 Sep; 72(9):1433-5. PubMed ID: 23625979 [No Abstract] [Full Text] [Related]
2. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. Genovese MC; Bojin S; Biagini IM; Mociran E; Cristei D; Mirea G; Georgescu L; Sloan-Lancaster J Arthritis Rheum; 2013 Apr; 65(4):880-9. PubMed ID: 23359344 [TBL] [Abstract][Full Text] [Related]
3. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Devine EB; Alfonso-Cristancho R; Sullivan SD Pharmacotherapy; 2011 Jan; 31(1):39-51. PubMed ID: 21182357 [TBL] [Abstract][Full Text] [Related]
5. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435 [TBL] [Abstract][Full Text] [Related]
6. Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007? Yazici Y; Abramson SB Bull NYU Hosp Jt Dis; 2007; 65(4):300-5. PubMed ID: 18081549 [TBL] [Abstract][Full Text] [Related]
7. Use of prognostic markets to guide biologic therapies for rheumatoid arthritis. D'Arcy CA; Willkens RF J Rheumatol; 2002 Dec; 29(12):2662; author reply 2662-3. PubMed ID: 12465172 [No Abstract] [Full Text] [Related]
8. COBRA combination therapy in daily practice--getting back to the future. Boers M Rheumatology (Oxford); 2008 Jan; 47(1):1-2. PubMed ID: 18077485 [No Abstract] [Full Text] [Related]
9. [Combination therapy for rheumatoid arthritis]. Sibilia J Ann Med Interne (Paris); 2002 Feb; 153(1):41-52. PubMed ID: 11994689 [TBL] [Abstract][Full Text] [Related]
10. Adalimumab for rheumatoid arthritis? Ebell M; Kripke C Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667 [No Abstract] [Full Text] [Related]
12. [Treatment of rheumatoid arthritis with adalimumab. Results from a Cochrane review]. Pedersen SJ; Hetland ML; Østergaard M Ugeskr Laeger; 2006 Aug; 168(35):2899-903. PubMed ID: 16982019 [No Abstract] [Full Text] [Related]
13. Cancer drug approved for RA. Health News; 2006 Apr; 12(4):2. PubMed ID: 16572516 [No Abstract] [Full Text] [Related]
14. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Singer O; Gibofsky A Curr Opin Rheumatol; 2011 May; 23(3):288-92. PubMed ID: 21378570 [TBL] [Abstract][Full Text] [Related]
15. [Experiences with infliximab in the treatment of active rheumatoid arthritis and spondyloarthropathy]. Dahlin J; Sørensen SF Ugeskr Laeger; 2003 Nov; 165(48):4646-9. PubMed ID: 14677464 [No Abstract] [Full Text] [Related]
16. New drugs for rheumatoid arthritis. Messori A; Santarlasci B; Vaiani M N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436 [No Abstract] [Full Text] [Related]
17. [Lesson from ACR guidelines for management of RA]. Abe T Nihon Rinsho; 2005 Jan; 63 Suppl 1():431-8. PubMed ID: 15799394 [No Abstract] [Full Text] [Related]
18. Anticytokine therapy--a new era in the treatment of rheumatoid arthritis? O'Dell JR N Engl J Med; 1999 Jan; 340(4):310-2. PubMed ID: 9920958 [No Abstract] [Full Text] [Related]